Search
User Profile
Change
Select your user profile
Eventi

European Congress of Pathology (ECP)

vieni a trovarci allo stand 15

36th ECP
European Congress of Pathology


7 - 11 September 2024
Fortezza da Basso, Firenze

Register now

Driving diagnostic certainty for life-changing decisions in pathology

ECP is the worldwide leading congress in pathology. This year’s theme, “Multi-dimensional pathology – cornerstone of modern diagnostics,” reflects the idea that it is pathology’s continuous integration of novel technologies while safely relying on classical histology that has made the field one of the forefront innovation drivers in medicine and a key player in medical decision-making. ECP 2024 is dedicated to providing up-to-date insights into the whole spectrum of modern diagnostics, translational tools and achievements that characterise pathology and its contribution to innovative diagnostics.

Roche, as a global leader in oncology, personalised healthcare and companion diagnostics, is a long-standing partner of the pathology community and a premium sponsor for this year’s meeting. We will offer a full agenda of activities focused on advancing science to deliver high medical value innovations that empower pathology professionals to impact outcomes and change lives. 

We look forward to welcoming attendees for Roche-sponsored educational symposia, in-booth talks and much more.

Please sign up to receive additional details as they are available, or check back here.

Register now

Browse the programme

Roche symposia

Roche booth 

In-booth talks 

 

Symposia

9 September 2024
07:15 - 08:15 CET
Location: Spadolini 7


Roche Symposium


Improving the diagnosis of B-cell lymphomas in routine pathology practice: Advances in clonality evaluation

B-cell lymphomas can represent a diagnostic challenge due to significant overlap in clinical and morphologic features with reactive lymphoid proliferations, and traditional methods of determining clonality are limited by sub-optimal sensitivity and/or cumbersome workflows. The ultra-sensitive VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay for light chain restriction will be discussed, with descriptive cases illustrating its utility.
 

  • Dr Teresa Marafioti, Professor, University College London
  • Dr Marta Canamero, Medical Affairs Lead, Roche Diagnostics

Moderator: Bowdoin Su, Medical Affairs Lead, Roche Diagnostics

9 September 2024
13:00 - 14:30 CET
Location: Spadolini 7  

Roche and Johnson & Johnson
Joint Symposium

Pathways to precision: Practical strategies for optimising diagnostic excellence

In this precision pathology symposium we delve into key challenges and opportunities within the biomarker testing pathway. Leading pathologists will unveil innovative solutions they've successfully implemented in their laboratories, enhancing both diagnostic precision and operational efficiency. Through interactive sessions including roundtable discussions and best practice sharing, attendees will gain invaluable insights to inspire advancements in their own practice.
 

  • Introduction: Testing pathway and patient leakage points
    Pr Angelo Dei Tos, Professor of Pathology at Padua University Hospital (AOUP), Italy
  • Increasing identification of patients with actionable target
    Pr Deniz Nart, Professor of Pathology at Ege University (EU) Hospital, Turkey
  • Optimising the workflow to reduce failure rates
    Pr Sylvie Lantuejoul, Centre Léon Bérard, France
  • Implementation of one NGS flow to reduce turnaround time
    Pr Isabelle Vanden Bempt, Clinical Biologist at UZ Leuven, Belgium

Pr Angelo Dei Tos will chair the session

10 September 2024
13:00 - 14:30 CET
Location: Spadolini 7  


Roche Symposium


Precision diagnostics in ovarian cancer: Traversing from testing to treatment

This session will highlight the history and current landscape of biomarker testing in ovarian cancer (OC) and how these markers have transformed therapy options for ovarian cancer patients. The session will highlight the newest biomarker, folate receptor alpha (FRɑ), and how identifying patients eligible for FRɑ-targeted therapy using the FDA approved VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay has shaped the treatment landscape for patients with platinum-resistant OC. The session will feature oncologist and pathologist panel speakers to give their perspectives on the ovarian cancer patient journey and incorporation of IHC FRɑ testing in this disease and will conclude with a discussion around best practices for implementing FRɑ testing for OC patients in EU countries and key considerations for both pathologists and oncologists.
 

  • Dr Michelle Shiller, Medical Director Cancer Genetics, Baylor Sammons Cancer Center and National Medical Director, Genomics and Molecular Pathology Services, PathGroup, US
  • Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology, Humanitas University and Director, Medical Gynaecology Oncology Unit, Humanitas San Pio X Hospital, Italy

Dr Megan Dumas, Global Medical Affairs Lead, Roche Diagnostics, will chair the session

 

Find us at booth 15

As a global leader in companion diagnostics, we passionately believe that precision medicine has the power to radically transform lives. Throughout each patient’s cancer journey, diagnostic testing plays a critical role in supporting clinicians in making decisions that can lead to better outcomes. Our exhibition this year will focus on highlighting high medical value innovations that help pathologists deliver the answers clinicians rely on to provide the highest standard of care.

Roche medical and product experts will be on hand to discuss our portfolio across the pathology and molecular work areas. Booth talks will also offer an opportunity to engage with some of our pharmaceutical partners whose therapeutic advancements are helping fuel our pipeline of innovative high medical value assays and AI-based clinical decision support solutions.

We are hosting a number of in-booth talks that explore of-the-moment topics at the Roche booth # 15 – read on to learn more! By signing up below, you will also gain access to our ECP virtual event hub where you can explore post-event recordings of in-booth talks as well as Roche-sponsored symposia. 

In-booth talk

 

  • Sunday, 8 September 2024


at Roche booth # 15

13:10 - 13:30 CET
PIK3CA: Leveraging emerging insights to drive personalised care

  • Dr Nicola Fusco, Director, Division of Pathology at IEO European Institute of Oncology, Department of Oncology and Hematology-Oncology, University of Milan


PI3K pathway plays a major role in HR+ cancer biology, and identification of PIK3CAmut is vitally important to optimising patient outcomes. Testing immediately post-adjuvant progression should be embedded in diagnosis pathways; a multidisciplinary approach to minimise turnaround times and maximise the testing opportunity is critical.


14:00 - 14:20 CET
The Roche Digital LightCycler: A real world performance evaluation in a Dutch hospital laboratory

  • Dr Wouter Pattje, Lead Systems Engineer, dPCR Development, Roche Diagnostics


Digital PCR (dPCR) is a powerful tool that is transforming clinical research in oncology. The Roche Digital LightCycler demonstrates exquisite sensitivity, absolute quantification and remarkable precision. Analytic performance data from a prototype multiplex EGFR dPCR assay will be presented.

In-booth talk

 

  • Monday, 9 September 2024


at Roche booth # 15

13:10 - 13:30 CET
Advancing precision medicine: PathAI and Roche collaborate for AI-powered companion diagnostics

  • Dr Eric Walk, Chief Medical Officer, PathAI
  • Michael Rivers, Lifecycle Leader, Digital Pathology, Roche Diagnostics


PathAI and Roche discuss how together, they are advancing precision medicine through AI-powered companion diagnostics.


14:00 - 14:20 CET
Seamless integration of Ibex’s AI algorithms within Roche’s navify® Digital Pathology

  • Stuart Shand, Chief Commercial Officer, Ibex
  • Michael Rivers, Lifecycle Leader, Digital Pathology, Roche Diagnostics


Ibex and Roche will discuss the benefits of a seamless integration between AI algorithms and pathology workflow software.


16:40 - 17:00 CET
Unlock the power of in-house comprehensive genomic profiling (CGP) with AVENIO Tumor Tissue CGP Kit V2 and the new Foundation Medicine HRD signature

  • Robert Bulte, Customer Area Network Lead, Roche Diagnostics
  • Dr Muriel De Vos, Global Medical Affairs Lead, Oncology & Genetics, Roche Diagnostics


Increased adoption of personalised medicine has brought comprehensive genomic profiling to the forefront of cancer research. CGP testing maximizes all relevant information obtained from (limited) biopsy samples, and is ideally straightforward to implement and operate in the laboratory. Learn about the latest Roche AVENIO Tumor Tissue CGP Kit V2 with a panel and bioinformatics based on FoundationOne®CDx, offering fast and optimised NGS workflows, and a novel HRD signature in addition to other complex genomic signatures.

In-booth talk

 

  • Tuesday, 10 September 2024


at Roche booth # 15

13:10 - 13:30 CET
Gastric cancer testing landscape in 2024 and beyond

  • Dr Mar Iglesias, Associate Professor and Head of Pathology, Hospital del Mar, Barcelona


This talk will demonstrate the testing workflow for gastric and gastroesophageal junction cancers in the context of current practice guidelines. Impact of new and emerging biomarkers such as CLDN18 and FGFR2b will be discussed.

Sign up here to receive updates and exclusive content access

 

Complete this form to stay up to date with all things to do with Roche at ECP 2024!

You will also gain exclusive access to our ECP 2024 webpage, where you can explore curated content including recordings of symposia and in-booth talks.

 

Verrai ricontattato al più presto
Richiesta inviata correttamente!
text
close

Related information

...
    ...

    Reference:

    1. cobas HIV-1/HIV-2, Qualitative nucleic acid test for use on the cobas 5800/6800/8800 Systems US-IVD Method Sheet 09198695001-05EN